These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 22863482)

  • 21. Early detection of Parkinson's disease: unmet needs.
    Gerlach M; Hendrich A; Hueber R; Jost W; Winkler J; Woitalla D; Riederer P
    Neurodegener Dis; 2008; 5(3-4):137-9. PubMed ID: 18322371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers for the diagnosis and management of Parkinson's disease.
    Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M
    Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early diagnosis of Parkinson's disease and initiation of treatment.
    Weiner WJ
    Rev Neurol Dis; 2008; 5(2):46-53; quiz 54-5. PubMed ID: 18660736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF α-synuclein does not differentiate between parkinsonian disorders.
    Aerts MB; Esselink RA; Abdo WF; Bloem BR; Verbeek MM
    Neurobiol Aging; 2012 Feb; 33(2):430.e1-3. PubMed ID: 21236518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
    Kalia LV
    Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical premotor biomarkers for Parkinson's disease.
    Mollenhauer B; Zhang J
    Mov Disord; 2012 Apr; 27(5):644-50. PubMed ID: 22508282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
    Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
    Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers in Parkinson's disease.
    Dorsey ER; Holloway RG; Ravina BM
    Expert Rev Neurother; 2006 Jun; 6(6):823-31. PubMed ID: 16784406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease.
    Schmid SP; Schleicher ED; Cegan A; Deuschle C; Baur S; Hauser AK; Synofzik M; Srulijes K; Brockmann K; Berg D; Maetzler W
    Mov Disord; 2012 Feb; 27(2):288-92. PubMed ID: 22021190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers for Parkinson's disease.
    Graeber MB
    Exp Neurol; 2009 Apr; 216(2):249-53. PubMed ID: 19166835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical biomarkers of Parkinson disease.
    Wu Y; Le W; Jankovic J
    Arch Neurol; 2011 Jan; 68(1):22-30. PubMed ID: 21220674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials.
    Lang AE
    Mov Disord; 2011 Apr; 26(5):775-83. PubMed ID: 21484865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers for Parkinson's disease.
    Sherer TB
    Sci Transl Med; 2011 Apr; 3(79):79ps14. PubMed ID: 21508309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease: epidemiology, (differential) diagnosis, therapy, relation to dementia.
    Oertel WH
    Arzneimittelforschung; 1995 Mar; 45(3A):386-9. PubMed ID: 7763330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early diagnosis in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1992; 38():105-14. PubMed ID: 1491243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
    Frank T; Klinker F; Falkenburger BH; Laage R; Lühder F; Göricke B; Schneider A; Neurath H; Desel H; Liebetanz D; Bähr M; Weishaupt JH
    Brain; 2012 Jun; 135(Pt 6):1914-25. PubMed ID: 22427327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
    Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
    Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.